91
Participants
Start Date
August 1, 2017
Primary Completion Date
June 20, 2019
Study Completion Date
June 20, 2019
Placebo Inhalation Solution
Normal Saline Inhalation Solution
SPX-101
SPX-101 Inhalation Solution
University of Calgary Heritage Medical Research Center, Calgary
Ottawa Hospital Research Institute/Institut de Recherche de l'Hospital d'Ottawa, Ottawa
Saint Michael's Hospital, Toronto
Hospices Civils de Lyon (HCL), Pierre-Bénite
Centre Hospitalier Universitaire Brest, Roscoff
CHU de Rouen, Rouen
CHU de Montpellier, Montpellier
CHU de Angers, Angers
Hopital Pasteur, Nice
Assistance Publique-Hôpitaux de Paris Hôpital Cochin, Paris
Istituto Giannina Gaslini Ospedale Pediatrico, Genoa
Hospital de Santa Maria, Lisbon
Belfast Health and Social Care Trust, Belfast
Heart of England NHS Foundation Trust, Birmingham
University Hospitals Bristol NHS Foundation Trust, Bristol
Western General Hospital - NHS Lothian, Edinburgh
Royal Devon and Exeter NHS Foundation Trust, Exeter
NHS Greater Glasgow and Clyde, Glasgow
The Leeds Teaching Hospitals NHS Trust, Leeds
Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool
Barts Health NHS Trust Saint Bartholomews Hospital, London
Royal Brompton and Harefield NHS Foundation Trust, London
University Hospital of South Manchester NHS Foundation Trust, Manchester
Newcastle Upon Tyne Hospitals, Newcastle upon Tyne
Nottingham University Hospitals NHS Trust, Nottingham
Spyryx Biosciences, Inc.
INDUSTRY